Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Biotech’s trade secrets face growing threat from foreign influences, science leaders warn

    June 8, 2023

    Canadian biotech narrows trial population to lift solid tumor drug out of FDA hold

    June 7, 2023

    Biotechs face challenges as the industry’s annual bash returns to Boston

    June 5, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      Biotech’s trade secrets face growing threat from foreign influences, science leaders warn

      June 8, 2023

      Canadian biotech narrows trial population to lift solid tumor drug out of FDA hold

      June 7, 2023

      Biotechs face challenges as the industry’s annual bash returns to Boston

      June 5, 2023

      The Biotech Buying Bonanza: Why The FTC’s Amgen Battle Won’t Chill The Spree

      June 5, 2023

      China reaching for biotech breakthroughs in space

      June 2, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Bio Technology»FDA Approves Interchangeable Biosimilar Insulin
    Bio Technology

    FDA Approves Interchangeable Biosimilar Insulin

    yourbiotechBy yourbiotechFebruary 20, 2022No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    FDA has authorised Mylan Pharmaceuticals’ Semglee, the first interchangeable biosimilar insulin product for treating diabetes.

    On July 28, 2021, FDA authorized Mylan Pharmaceuticals’ Semglee (insulin glargine-yfgn), the first interchangeable biosimilar insulin product inside the United States for treating diabetes. The product is indicated for improving glycemic manipulate in adults and pediatric sufferers with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. Semglee is both biosimilar to and interchangeable with its reference product, Lantus (insulin glargine), a protracted-performing insulin analog.

    According to FDA, an interchangeable biosimilar product may be substituted for the reference product and does now not require the intervention of a prescriber. Substitution may occur at pharmacy level, similar to how everyday pills are substituted for brand call pills, challenge to nation pharmacy legal guidelines, which vary by nation. Similar to familiar-drug price savings, biosimilar and interchangeable biosimilar products have the capacity to lessen health care expenses. Biosimilars advertised within the US have generally released at preliminary list charges that are 15% to 35% decrease than comparative listing expenses of the reference product, the organization said in a press launch.

    The approval of Semglee is based totally on evidence that confirmed it’s miles surprisingly much like the reference product, Lantus, and that there aren’t any clinically significant differences among the 2 in terms of protection, purity, and potency. Evidence additionally showed that Semglee may be expected to provide the same clinical result as Lantus and that the safety and efficacy risks in switching from Lantus to Semglee are no more than the risks of using Lantus without switching.

    “This is a momentous day for folks who depend each day on insulin for treatment of diabetes, as biosimilar and interchangeable biosimilar merchandise have the capacity to substantially reduce fitness care costs,” stated Acting FDA Commissioner Janet Woodcock in the press release. “Today’s approval of the primary interchangeable biosimilar product furthers FDA’s longstanding commitment to support a aggressive market for organic products and in the long run empowers sufferers by means of supporting to increase get admission to to safe, effective, and brilliant medicines at potentially decrease price.”

    “Access to inexpensive insulin is crucial, and long-acting insulin products, [such as] insulin glargine, play an important position within the remedy of Types 1 and a pair of diabetes mellitus,” stated Peter Stein, director of the Office of New Drugs in FDA’s Center for Drug Evaluation and Research. “[FDA’s] high requirements for approval imply fitness care professionals and patients can be assured inside the safety and effectiveness of an interchangeable biosimilar product, simply as they might for the reference product.”

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleWhy we must improve clinical trial diversity and how?
    Next Article PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend
    yourbiotech
    • Website

    Related Posts

    Biotech’s trade secrets face growing threat from foreign influences, science leaders warn

    June 8, 2023

    Canadian biotech narrows trial population to lift solid tumor drug out of FDA hold

    June 7, 2023

    Biotechs face challenges as the industry’s annual bash returns to Boston

    June 5, 2023

    The Biotech Buying Bonanza: Why The FTC’s Amgen Battle Won’t Chill The Spree

    June 5, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.